KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Change in Account Payables (2019 - 2025)

GoodRx Holdings' Change in Account Payables history spans 7 years, with the latest figure at -$10.5 million for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 243.2% year-over-year to -$10.5 million; the TTM value through Dec 2025 reached $4.1 million, up 125.94%, while the annual FY2025 figure was $4.1 million, 125.94% up from the prior year.
  • Change in Account Payables for Q4 2025 was -$10.5 million at GoodRx Holdings, down from $3.5 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $25.5 million in Q3 2023 and bottomed at -$15.6 million in Q2 2024.
  • The 5-year median for Change in Account Payables is -$115000.0 (2021), against an average of $322736.8.
  • The largest YoY upside for Change in Account Payables was 10030.77% in 2022 against a maximum downside of 933.78% in 2022.
  • A 5-year view of Change in Account Payables shows it stood at -$115000.0 in 2021, then soared by 6306.09% to $7.1 million in 2022, then skyrocketed by 257.11% to $25.5 million in 2023, then crashed by 71.17% to $7.3 million in 2024, then plummeted by 243.2% to -$10.5 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Change in Account Payables are -$10.5 million (Q4 2025), $3.5 million (Q3 2025), and $10.8 million (Q2 2025).